Navigation Links
Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
Date:10/10/2007

PALO ALTO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today the appointment of its C.E.O., Belinda Tsao-Nivaggioli, Ph.D., to the additional role of Chairman of the Company's Board of the Directors. Dr. Tsao- Nivaggioli succeeds Nasser Menhall, who recently resigned from the Board to focus his time on other business ventures.

"I want to take this opportunity to thank Nasser for his many contributions and his invaluable leadership over many years and I wish him best of luck in his new ventures," stated Dr. Tsao-Nivaggioli. "I appreciate the Board of Directors' vote of confidence and I continue to be proud to be associated with this organization and its people. I look forward to leading this Company and to further leveraging our cellular energy technology to develop and commercialize pharmaceutical and dermaceutical products."

Prior to her current roles of CEO and Chairman, Dr. Tsao-Nivaggioli was Avicena's chief operating officer from 2002 to 2004. During her tenure with the Company, Dr. Tsao-Nivaggioli has expanded its intellectual property portfolio and built a substantial pipeline of pharmaceutical products, including drug candidates for the treatment of neurological disorders such as ALS, Huntington's and Parkinson's Disease. Dr. Tsao-Nivaggioli is also credited with solidifying the Company's relationship with the National Institutes of Health (NIH) as well as developing the Company's dermaceutical programs.

ABOUT AVICENA

Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:

The Ruth Group (on behalf of Avicena Group)

Sara Ephraim (investors)

(646) 536-7002

sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)

(646) 536-7033 / 7025

jmccargo@theruthgroup.com or jrando@theruthgroup.com


'/>"/>
SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Avicena to Advance Huntingtons Disease Clinical Program into Phase III
2. Study casts doubt on keyboard ills
3. Who Board To Discuss Asian Tsunami Related Health Issues
4. Abdominal Crunches Not The Best Option For Wash Board Abs.
5. Computer Keyboards In Hospitals Could Spread Infection To Patients
6. Flu, Boarded A Ship?
7. Skateboarding to health
8. Shangai Citizens to Monitor Billboards
9. Budhia Is Fine, Government-constituted Medical Board Reports False
10. Pharmacy Board Says Pharmacists Have Right To Refuse Morning-After Pill
11. 115 people on board a cruise liner taken ill due to suspected Norovirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... in Central Michigan, has produced another video highlighting one of the many supplemental ... Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt in the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
(Date:5/25/2016)... MA (PRWEB) , ... May 25, 2016 , ... ... Research Institute (WCRI) compare outcomes of injured workers across 15 states. The ... to work, earnings recovery, access to medical care, and satisfaction with medical care. ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of the ... ran one of Allstate’s most successful agencies for 48 years, but it was his ... award named for him is not given every year, but only when an agency ...
(Date:5/25/2016)... Puerto Vallarta, Mexico (PRWEB) , ... May 25, 2016 , ... ... menu surrounding the restorative properties of precious stones to complement its new wellness ... spread over two floors and feature a plethora of special services and insuite amenities, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
(Date:5/24/2016)... 24, 2016 Celsion Corporation (NASDAQ: ... today provided an update on its ongoing OVATION ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... is an IL-12 DNA plasmid vector formulated as ...
(Date:5/24/2016)... , May 24, 2016 Open ... in Clinical Neurophysiology  Elsevier , a ... and services, today announced the launch of ... access journal that focuses on clinical practice issues in ... reports, clinical series, normal values and didactic reviews. It ...
Breaking Medicine Technology: